For research use only. Not for therapeutic Use.
Candoxatril is the orally active prodrug of candoxatrilat (UK-73967) human neutral endopeptidase (Neprilysin) as the neutral endopeptidase 24.11 complexed (RB-101) with phosphoramidon degrades and inactivates a number of bioactive peptides. Two multiply connected folding domains of the neutral endopeptidase locus splicing of exons 1, 2a, or 2b to the common exon 3 composed of 24 exons of the human CALLA/NEP gene containing the active site, it is known as peptidase family M13 the gluzincins a faint but significant structural relationship of the metzincins to the thermolysin-like enzymes, Zincin is the simplest descriptor of biological space.
| Catalog Number | M023632 |
| CAS Number | 118785-03-8 |
| Molecular Formula | C29H41NO7 |
| Purity | ≥95% |
| Storage | Desiccate at -20C |
| IUPAC Name | 4-[[1-[3-(2,3-dihydro-1H-inden-5-yloxy)-2-(2-methoxyethoxymethyl)-3-oxopropyl]cyclopentanecarbonyl]amino]cyclohexane-1-carboxylic acid |
| InChI | InChI=1S/C29H41NO7/c1-35-15-16-36-19-23(27(33)37-25-12-9-20-5-4-6-22(20)17-25)18-29(13-2-3-14-29)28(34)30-24-10-7-21(8-11-24)26(31)32/h9,12,17,21,23-24H,2-8,10-11,13-16,18-19H2,1H3,(H,30,34)(H,31,32) |
| InChIKey | ZTWZVMIYIIVABD-UHFFFAOYSA-N |
| SMILES | COCCOCC(CC1(CCCC1)C(=O)NC2CCC(CC2)C(=O)O)C(=O)OC3=CC4=C(CCC4)C=C3 |
| Reference | </br>1:Effect of Treatment of Sprague Dawley Rats with AVE7688, Enalapril, or Candoxatril on Diet-Induced Obesity. Davidson EP, Coppey LJ, Dake B, Yorek MA.J Obes. 2011;2011. pii: 686952. doi: 10.1155/2011/686952. Epub 2010 Aug 16. PMID: 20847891 Free PMC Article</br>2:The endopeptidase inhibitor, candoxatril, and its therapeutic potential in the treatment of chronic cardiac failure in man. McDowell G, Nicholls DP.Expert Opin Investig Drugs. 1999 Jan;8(1):79-84. PMID: 15992061 </br>3:Me-DuPHOS-Rh-Catalyzed Asymmetric Synthesis of the Pivotal Glutarate Intermediate for Candoxatril. Burk MJ, Bienewald F, Challenger S, Derrick A, Ramsden JA.J Org Chem. 1999 Apr 30;64(9):3290-3298. PMID: 11674433 </br>4:Placebo-controlled comparison of candoxatril, an orally active neutral endopeptidase inhibitor, and captopril in patients with chronic heart failure. Northridge DB, Currie PF, Newby DE, McMurray JJ, Ford M, Boon NA, Dargie HJ.Eur J Heart Fail. 1999 Mar;1(1):67-72. PMID: 10937982 Free Article</br>5:Hemodynamic and neuroendocrine effects for candoxatril and frusemide in mild stable chronic heart failure. Westheim AS, Bostrøm P, Christensen CC, Parikka H, Rykke EO, Toivonen L.J Am Coll Cardiol. 1999 Nov 15;34(6):1794-801. PMID: 10577572 Free Article</br>6:Comparison of the short-term effects of candoxatril, an orally active neutral endopeptidase inhibitor, and frusemide in the treatment of patients with chronic heart failure. Northridge DB, Newby DE, Rooney E, Norrie J, Dargie HJ.Am Heart J. 1999 Dec;138(6 Pt 1):1149-57. PMID: 10577447 </br>7:Reproductive study. II: Prenatal and postnatal development study with candoxatril in Sprague-Dawley rats. Horimoto M, Ito R, Isobe Y, Sakimura M, Tachibana M.J Toxicol Sci. 1998 Nov;23 Suppl 5:671-9. PMID: 9891906 </br>8:Candoxatril improves exercise capacity in patients with chronic heart failure receiving angiotensin converting enzyme inhibition. Newby DE, McDonagh T, Currie PF, Northridge DB, Boon NA, Dargie HJ.Eur Heart J. 1998 Dec;19(12):1808-13. PMID: 9886723 </br>9:Inhibition of kidney neutral endopeptidase after administration of the neutral endopeptidase inhibitor candoxatril: quantitation by autoradiography. Yoshida K, Kanazawa M, Casley DJ, Katopothis A, Johnston CI.J Cardiovasc Pharmacol. 1998 Nov;32(5):702-8. PMID: 9821842 </br>10:Formation and pharmacokinetics of the active drug candoxatrilat in mouse, rat, rabbit, dog and man following administration of the prodrug candoxatril. Kaye B, Brearley CJ, Cussans NJ, Herron M, Humphrey MJ, Mollatt AR.Xenobiotica. 1997 Oct;27(10):1091-102. PMID: 9364744 |
